We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Unity Biotechnology Inc (UBX) USD0.0001

Sell:$1.88 Buy:$1.89 Change: $0.04 (2.07%)
Market closed |  Prices as at close on 2 December 2021 | Switch to live prices |
Change: $0.04 (2.07%)
Market closed |  Prices as at close on 2 December 2021 | Switch to live prices |
Change: $0.04 (2.07%)
Market closed |  Prices as at close on 2 December 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Unity Biotechnology, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of programs targeting specific biological mechanisms implicated in diseases of aging. The Company is also developing systemic senolytic medicines using multiple modalities, including small molecules, antisense oligonucleotides and biologics. Its product portfolio includes UBX1325, UBX2050 and UBX2089. It targets cellular senescence and advancing senolytic programs in ophthalmologic and neurologic disorders. The Company also advancing other programs based on other biologies of aging, including an agonistic antibody to the Tie2 receptor to treat vascular eye disease and α-Klotho hormone to treat cognitive disorders.

Contact details

3280 Bayshore Blvd
United States
+1 (650) 4161192

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$126.99 million
Shares in issue:
57.72 million
United States
US dollar

Key personnel

  • Keith Leonard
    Chairman of the Board
  • Anirvan Ghosh
    Chief Executive Officer, Director
  • Luis Visoso
    Chief Financial Officer, Senior Vice President
  • Nathan Guz
    Vice President - Operations
  • Jason Damiano
    Vice President of Translational Biology
  • Alexander Nguyen
    General Counsel and Corporate Secretary
  • Jamie Dananberg
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.